Shanghai Innogen Pharmaceutical Technology Co., Ltd. (Innogen) presented several studies of efsubaglutide alfa injection at the 82nd American Diabetes Association (ADA) Scientific Sessions.
Four studies were presented as posters:
A study of single and repeated efsubaglutide alfa administration in rats and monkeys, examining pharmacokinetics and pharmacodynamics, together with its main distribution and elimination routes in rats.
A study of GABA plus sitagliptin in preventing high-fat-diet-induced beta-cell injury, investigating the combination's effects on beta-cell proliferation and the mechanisms involved.
A study of a single dose of efsubaglutide alfa in healthy volunteers, assessing safety, tolerability, pharmacokinetics and pharmacodynamics.
A study of single and repeated efsubaglutide alfa dosing in people with type 2 diabetes, assessing safety, tolerability, pharmacokinetics and pharmacodynamics.
An oral presentation at the European Association for the Study of Diabetes (EASD) meeting was also planned for the study 'GABA and Sitagliptin Prevent Impairment of Beta-Cell Function Caused by High-Fat Diet.' Led by Professor Qinghua Wang, the research examined how GABA and sitagliptin promote beta-cell proliferation. Excessive beta-cell loss and the resulting deficits in insulin secretion and action are important contributors to diabetes. Understanding the cellular and molecular mechanisms of beta-cell proliferation could provide a basis for safe, effective beta-cell-targeted treatments.
The ADA Scientific Sessions is one of the world's largest and most important diabetes meetings, attracting tens of thousands of clinicians and researchers each year to share major advances in diabetes research and treatment. Innogen and its collaborating clinical experts present basic and clinical findings on efsubaglutide alfa at the meeting annually. Innogen also planned an oral presentation at EASD in Stockholm, September 19–23, 2022.
The 2022 ADA meeting took place June 3–7 in New Orleans, with both in-person and online participation.
Innogen presentations
Poster presentation — ADA
Poster number: 256-LB.
Poster title: GABA and Sitagliptin Prevent Impairment of Beta-Cell Function Caused by High-Fat Diet
Presentation time: Sunday, June 5, 2022, 12:00–13:00
Location: ePoster, Halls D–E
Session: Islet Biology — Beta Cell — Stimulus–Secretion Coupling and Metabolism
Poster presentation — ADA
Poster number: 88-LB.
Poster title: Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Weekly Efsubaglutide Alfa in People with Type 2 Diabetes
Presentation time: Sunday, June 5, 2022, 12:00–13:00
Location: ePoster, Halls D–E
Session: Clinical Therapeutics/New Technology — Incretin-Based Therapies
Poster presentation — ADA
Poster number: 93-LB
Poster title: A Randomised Clinical Trial of the Safety, Pharmacokinetics and Pharmacodynamics of Weekly Dosing in Healthy Chinese Participants
Presentation time: Sunday, June 5, 2022, 12:00
Location: ePoster, Halls D–E
Session: Clinical Therapeutics/New Technology — Incretin-Based Therapies
Poster presentation — ADA
Poster number: 83-LB.
Poster title: Pharmacokinetic and Pharmacodynamic Studies of Efsubaglutide Alfa in Rats and Monkeys
Presentation time: Sunday, June 5, 2022, 12:00–13:00
Location: ePoster, Halls D–E
Session: Clinical Therapeutics/New Technology — Incretin-Based Therapies
Oral presentation — EASD
Presentation number: 285
Presentation title: GABA and Sitagliptin Prevent Impairment of Beta-Cell Function Caused by High-Fat Diet
Presentation time: Wednesday, September 21, 2022, 12:00–13:00
Session: Short Oral Discussion Event C
About efsubaglutide alfa injection
The company described efsubaglutide alfa injection as China's first domestically developed human, long-acting GLP-1 medicine with independently owned intellectual property, being developed for type 2 diabetes and related metabolic diseases. It stated that the molecule promotes insulin secretion and pancreatic beta-cell regeneration and improves beta-cell quality, offering a potential approach to both the manifestations and underlying mechanisms of diabetes.
About Innogen
Founded in 2014, Innogen is a technology- and innovation-driven pharmaceutical research, development and manufacturing company with an international outlook. It focuses on biological medicines for diabetes and metabolic disease. Its management team brings together Chinese and international diabetes and endocrinology experts, experienced drug developers and business operators. The company has a genetically engineered recombinant-protein platform for developing and producing biological medicines, multiple diabetes and metabolic-disease programs and technologies with global intellectual property, and what it describes as internationally advanced translational diabetes research.